Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
GlobalData on MSN23h
Amgen speaks out about bone density concerns with obesity drugAmgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its ...
Summary of Quarterly Results (All Amounts are for the Three Month Period) The Company ended the first quarter of fiscal 2025 with $32.8 million in current assets, as compared to $17.6 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback